BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34407581)

  • 1. [Cost-effectiveness of anti-tumor associated antigen autoantibody screening for hepatocellular carcinoma in the population with chronic hepatitis B-related cirrhosis].
    Zhang M; Li YG; Wang KY; Wang X; Dai LP; Wang P; Ye H; Shi JX; Yang XA; Zhang SX; Zhang JY
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(32):2544-2551. PubMed ID: 34407581
    [No Abstract]   [Full Text] [Related]  

  • 2. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
    Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
    Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China].
    Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456
    [No Abstract]   [Full Text] [Related]  

  • 5. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis.
    Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Jackson S; Ryder S; Cramp M; Stein K
    Br J Cancer; 2008 Apr; 98(7):1166-75. PubMed ID: 18382459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost-effectiveness analysis.
    Nan Y; Garay OU; Lu X; Zhang Y; Xie L; Niu Z; Chen W
    J Comp Eff Res; 2024 Apr; 13(4):e230146. PubMed ID: 38415341
    [No Abstract]   [Full Text] [Related]  

  • 7. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis.
    Arguedas MR; Chen VK; Eloubeidi MA; Fallon MB
    Am J Gastroenterol; 2003 Mar; 98(3):679-90. PubMed ID: 12650806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma surveillance based on the Australian Consensus Guidelines: a health economic modelling study.
    Nguyen ALT; Si L; Lubel JS; Shackel N; Yee KC; Wilson M; Bradshaw J; Hardy K; Palmer AJ; Blizzard CL; de Graaff B
    BMC Health Serv Res; 2023 Apr; 23(1):378. PubMed ID: 37076870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients.
    Sangmala P; Chaikledkaew U; Tanwandee T; Pongchareonsuk P
    Asian Pac J Cancer Prev; 2014; 15(20):8993-9004. PubMed ID: 25374242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
    Toy M; Salomon JA; Jiang H; Gui H; Wang H; Wang J; Richardus JH; Xie Q
    Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis.
    Xie L; Yin J; Xia R; Zhuang G
    Hepatology; 2018 Oct; 68(4):1476-1486. PubMed ID: 29633304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area.
    Ungtrakul T; Mahidol C; Chun-On P; Laohapand C; Siripongsakun S; Worakitsitisatorn A; Vidhayakorn S; Boonchuay W; Dechma J; Sornsamdang G; Soonklang K; Sriprayoon T; Tanwandee T; Auewarakul CU
    World J Gastroenterol; 2016 Sep; 22(34):7806-12. PubMed ID: 27678364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms.
    Parikh ND; Singal AG; Hutton DW; Tapper EB
    Am J Gastroenterol; 2020 Oct; 115(10):1642-1649. PubMed ID: 32530829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
    Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening.
    Robotin MC; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy M; Penman AG
    J Hepatol; 2009 May; 50(5):990-8. PubMed ID: 19303657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-effectiveness of HCV testing strategies for hepatitis C elimination in general population in China].
    Liu PC; Xu D; Ding GW; Zhao L; Yu JJ; Liu ZF; Li J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2024 Mar; 45(3):464-472. PubMed ID: 38514325
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B.
    Kim HL; Kim GA; Park JA; Kang HR; Lee EK; Lim YS
    Gut; 2021 Nov; 70(11):2172-2182. PubMed ID: 33239344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
    Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
    Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis.
    Nahon P; Najean M; Layese R; Zarca K; Segar LB; Cagnot C; Ganne-Carrié N; N'Kontchou G; Pol S; Chaffaut C; Carrat F; Ronot M; Audureau E; Durand-Zaleski I; ; ; ;
    JHEP Rep; 2022 Jan; 4(1):100390. PubMed ID: 34977518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.
    Arnold E; Yuan Y; Iloeje U; Cook G
    Appl Health Econ Health Policy; 2008; 6(4):231-46. PubMed ID: 19382822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.